Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer

References

• Von Minckwitz G, Kaufmann M, Kuemmel S, Fasching PA, Eiermann W, Blohmer JU, et al., for the GBG and AGO-B Study Groups. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. J Clin Oncol 2011;29(Suppl):1028.
   Google Scholar
• Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, et al. Pathologic complete response after preoperative systemic therapy and outcome: Relevance of clinical and biologic baseline features. Breast Cancer Res Treat 2010;124:689–99.
   PubMed Web of Science ®Google Scholar
• Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2006;24:2019–27.
   PubMed Web of Science ®Google Scholar
• Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012;19:1508–16.
   PubMed Web of Science ®Google Scholar
• O’Brian MER, Wiger N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (CAELYXTM /Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440–9.
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trial 1989;10:1–10.
   PubMedGoogle Scholar
• Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17:3412–7.
   PubMed Web of Science ®Google Scholar
• Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999;17:3033–7.
   PubMed Web of Science ®Google Scholar
• Bujanda DA, Sarmiento UB, Suarez MAC, Ruiz MP, Gonzalez MAL, Morales JA. Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer. J Cancer Res Clin Oncol 2006;132:332–8.
   PubMed Web of Science ®Google Scholar
• Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 2005;23:2988–95.
   PubMed Web of Science ®Google Scholar
• Kelly H, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, et al. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/ cyclophosphamide. Clin Breast Cancer 2006;7:237–43.
   PubMed Web of Science ®Google Scholar
• Rocca A, Peruzzotti G, Ghisini R, Viale G, Veronesi P, Luini A, et al. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. Anticancer Drugs 2006;17:1201–9.
   PubMed Web of Science ®Google Scholar
• Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, Tiezzi MG. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 2007;7:36.
   PubMed Web of Science ®Google Scholar
• Gogas H, Papadimitriou C, Kalofonos HP, Bafaloukos D, Fountzilas G, Tsavdaridis D, et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: A phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 2002;13:1737–42.
   PubMed Web of Science ®Google Scholar
• Rossi D, Baldelli AM, Casadei V, Fedeli SL, Alessandroni P, Catalano V, et al. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer. Anticancer Drugs 2008;19:733–7.
   PubMed Web of Science ®Google Scholar
• Artioli G, Mocellin S, Borgato L, Cappetta A, Bozza F, Zavagno G, et al. Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer. Anticancer Res 2010;30: 3817–21.
   PubMed Web of Science ®Google Scholar
• Dellapasqua S, Mazza M, Rosa D, Ghisini R, Scarano E, Torrisi R, et al. Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. Breast 2011;20:319–23.
   PubMed Web of Science ®Google Scholar
• Taguchi T, Masuda N, Nakayama T, Motomura K, Tsukamoto F, Shimazu K, et al. Phase II trial in Japan of sequential administration of weekly paclitaxel followed by FEC as neoadjuvant chemotherapy for locally advanced breast cancer (KBCSG0206 trial: Kinki Breast Cancer Study Group (KBCSG)). Oncology 2010;78:302–8.
   PubMed Web of Science ®Google Scholar
• Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC- SAKK multicenter study. J Clin Oncol 2003;21: 843–50.
   PubMed Web of Science ®Google Scholar
• Gianni L, Semiglazov V, Manikhas GM, Eiermann W, Lluch A, Tjulandin S, et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis. J Clin Oncol 2007;25(Suppl): 532 (abstract)
   PubMedGoogle Scholar
• Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377–84.
   PubMed Web of Science ®Google Scholar
• Berrutoni A, Brizzi MP, Generali D, Ardine M, Dogliotti L, Bruzzi P, et al. Presurgical systemic treatment of nonmetastatic breast cancer: Facts and open questions. Oncologist 2008; 13:1137–48.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92.
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–84.
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676–85.
   PubMed Web of Science ®Google Scholar
• Bowles EJA, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Nat Cancer Inst 2012;104:1293–305.
   PubMed Web of Science ®Google Scholar
• Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicentre phase II trial. J Clin Oncol 2006; 24:2773–8.
   PubMed Web of Science ®Google Scholar
• Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20:1953–8.
   PubMed Web of Science ®Google Scholar
• Lindström L, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are instable throughout tumor progression. J Clin Oncol 2012;30: 2601–8.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurillo G, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice?Ann Oncol 2011;22:2227–33.
   PubMed Web of Science ®Google Scholar